Skip to content
naulon

Not checkedNot checked for notices yet.

Management of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors

Jiaxin ZHOU, Qian WANG, Lian DUAN and 8 more

Chinese Journal of Lung Cancer · 2019

doi:10.3779/j.issn.1009-3419.2019.10.12 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Immune checkpoint inhibitors (ICIs) have made remarkable breakthroughs in cancer treatment. However, the widely use of ICIs is associated with a spectrum of immune-related adverse events (irAEs). These adverse events can affect any organ system. In this article, we have made a systemic review about the clinical characteristics of rheumatic irAEs, and also summarized irAEs in patients with pre-exsiting rheumatic disease. We also focus on the management of rheumatic irAEs.

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.